[2] [3] However, there are recognised risks to be aware of: Nutrient deficiencies if food choices during eating windows are poor Disordered eating patterns , particularly in those with a history of restrictive eating Hypoglycaemia in individuals with diabetes or those taking insulin, sulfonylureas, or SGLT2 inhibitors these medication classes carry specific fasting-related risks and require review by a diabetes team before starting IF Fatigue, headaches, and difficulty concentrating , especially during the initial adaptation period Muscle loss if protein intake is insufficient alongside a significant calorie deficit The evidence base, whilst promising, is still evolving
In the warning section of a label (governed by specific FDA regulations), the mere reference to potential general gastrointestinal symptoms is insufficient to warn of the risks of the potential severity and longevity of gastroparesis, ileus, and intestinal blockage to which GLP-1RA users are exposed
S., Pless, N
Body weight loss percentage according to trial Estimated body weight loss percentage, normalised to 24 weeks More Speculative Peptide Drugs It suffices to say that anti-obesity drugs have undergone large gains in outcomes, larger average percentage decreases in weight and reductions in side-effects
Putting It Together Copper overload, oxidative stress, and undermethylation form a biochemical triangle that explains many of the behavioral and emotional symptoms seen in autism
However, individual results may vary based on diet, exercise, genetics, and overall health
